Jan G. J. Van de Winkel, Ph.D. Genmab CEO Rating
Where This Score Ranks Genmab's CEO Rating
- TOP10%
In the Top 10% of 2126 Similar Sized Companies on Comparably
- 1st
1st place versus 5 competitors rated on Comparably
Genmab CEO Jan G. J. Van de Winkel, Ph.D. Bio
Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. Dr. van de Winkel has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications.
Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University and also holds M.S. and Ph.D. degrees from the University of Nijmegen.
Dr. van de Winkel is a registered manager of Genmab with the Danish Business Authority.
Genmab CEO Jan G. J. Van de Winkel, Ph.D. At a Glance
The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Genmab.
Based on 25 ratings, Jan G. J. Van de Winkel, Ph.D. ranks right above GSK's CEO, Emma Walmsley.
Overall, the CEO score has remained stable over the last 90 days.
Genmab CEO Jan G. J. Van de Winkel, Ph.D. Rating Trendline
- Genmab79
- Similar Size on Comparably
Genmab's CEO Rating Rank Against Similar Sized Companies on Comparably
Genmab ranks in the Top 10% of other companies on Comparably with 1,001-5,000 Employees for CEO Rating Score.
